32.14

0.66% 0.21

Pre-market: 32.13 -0.010 -0.03%

Viking Therapeutics Inc (VKTX)

Overview News Price History Option Chain Financials Why VKTX Down? Discussions Forecast

Viking Therapeutics Inc stock is traded at $32.14, with a volume of 1.65M. It is up +0.66% in the last 24 hours and up +8.73% over the past month. Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Previous Close:

$31.93

Open:

$32.12

24h Volume:

1.65M

Relative Volume:

0.57

Market Cap:

$3.71B

Revenue:

Net Income/Loss:

$-237.39M

P/E Ratio:

-15.17

EPS:

-2.1183

Net Cash Flow:

$-224.58M

1W Performance:

-2.96%

1M Performance:

+8.73%

6M Performance:

+21.15%

1Y Performance:

+14.42%

1-Day Range:

$31.66

$32.63

1-Week Range:

$31.39

$33.96

52-Week Range:

$18.92

$43.15

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name

Viking Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

858-704-4660

Address

9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA

Employee

Twitter

@viking_vktx

Next Earnings Date

2025-10-22

Latest SEC Filings

VKTX's Discussions on Twitter

Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VKTX Viking Therapeutics Inc	32.14	3.69B	0	-237.39M	-224.58M	-2.1183
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-29-25	Initiated	Canaccord Genuity	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Goldman	Neutral
Feb-13-25	Initiated	Scotiabank	Sector Outperform
Feb-07-25	Initiated	Citigroup	Neutral
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy
Nov-04-24	Reiterated	H.C. Wainwright	Buy
Sep-11-24	Initiated	JP Morgan	Overweight
Jun-27-24	Initiated	Morgan Stanley	Overweight
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-26-24	Reiterated	Oppenheimer	Outperform
Mar-07-24	Initiated	Jefferies	Buy
Feb-28-24	Reiterated	Oppenheimer	Outperform
May-31-23	Resumed	ROTH MKM	Buy
Mar-28-23	Reiterated	Maxim Group	Buy
Mar-17-23	Initiated	Stifel	Buy
Jul-29-21	Resumed	BTIG Research	Buy
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform
Jun-05-20	Initiated	BMO Capital Markets	Outperform
May-05-20	Initiated	Chardan Capital Markets	Buy
May-01-20	Initiated	BTIG Research	Buy
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-25-19	Initiated	Stifel	Buy
Mar-29-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-14-19	Reiterated	Maxim Group	Buy
Feb-22-19	Initiated	SVB Leerink	Mkt Perform
Dec-12-18	Initiated	B. Riley FBR	Buy
Nov-19-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-18-18	Reiterated	H.C. Wainwright	Buy
Sep-18-18	Reiterated	Maxim Group	Buy
Sep-18-18	Reiterated	Raymond James	Outperform
Jul-20-18	Initiated	SunTrust	Buy
Jun-28-18	Initiated	Raymond James	Outperform
Jun-01-18	Reiterated	Laidlaw	Buy
May-31-18	Reiterated	Maxim Group	Buy
Mar-26-18	Resumed	H.C. Wainwright	Buy
Nov-28-17	Reiterated	Maxim Group	Buy
Nov-21-17	Initiated	ROTH Capital	Buy

View All

Viking Therapeutics Inc Stock (VKTX) Latest News

Mar 04, 2026

Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook - Finviz

Mar 04, 2026

Mar 03, 2026

VKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026